Rekenbi, an Alzheimer's treatment jointly developed by Japan and the US, has arrived in Japan... Expected to be launched in South Korea in 2025

Rekenbi, a new drug for Alzheimer's disease jointly developed by Japan's Eisai and America's Biogen, has landed on the Japanese market. In South Korea, approval will be obtained in the second half of next year and it will be released the year after next.
It is expected that According to the biotechnology industry, on the 17th, Eisai and Biogen officially launched LEQEMBI, a new drug for Alzheimer's disease, in Japan.
Rekenbi was approved in Japan on September 25th this year as a treatment for mild cognitive impairment caused by Alzheimer's disease and early Alzheimer's type dementia. Prior to release, an advisory body to the Ministry of Health, Labor and Welfare
The general meeting of the Central Social Insurance Medical Council approved the insurance coverage of ``Rekenbi.'' With this launch, Japan becomes the second country after the United States to market Rekenbi.
In Japan, it has been decided that public health insurance will cover up to 2.98 million yen per patient per year. In the US, one year's worth of drugs costs approximately $26,000.
(approximately 3.7 million yen). ``Rekenbi'' is a new type of drug that removes ``beta ARMYroid (βA),'' which is known as the causative agent of Alzheimer's disease.
It is the only treatment proven to slow cognitive decline in Alzheimer's patients. A Phase III clinical study found that after 18 months, the Rekenbi treatment group had significantly greater brain damage than the placebo group.
Cognitive decline was 27% slower. In the field of dementia treatment, the arrival of new drugs has received positive reviews. Eisai Biogen's "Aduhelm" will be launched in the US in 2021
The drug was approved in Japan, but there were problems with its efficacy. South Korea is also going through the process of obtaining permission. Eisai applied for product approval from the Ministry of Food and Drug Safety in the first half of this year. Korea
-Zai expects to receive item permit approval in the second half of next year. A pharmaceutical industry official said, ``The treatment of dementia still relies on drugs that have been on the market for over 20 years.''
"A new intravenous infusion like this would be meaningful for the patients we treat."